SRTS...Patented disruptive technology...Update on psoriasis & breast cancer treatment in yesterday's presentation...Two weeks ago Sensus submitted a product to FDA which will allow them to treat psoriasis for much less the cost of a current drug that costs approx $1000 a month, and the treatment will have the same (maybe better?) results. 19M people a year are treated for psoriasis. Huge, huge, huge, market. Already FDA approved in US, China, and Mexico for skin cancer treatment. Skin cancer market alone is 3x all other cancers combined. Also FDA approved in US and China for treating Keloids, another monster market. Sensus thinks the volume of patients to be treated for keloids is much greater than treatment of skin cancer. Targeting SRT approval in Latin America and Asia also.
Scalable Platform...From treating skin cancer, to keloids, to psoriasis, to breast cancer and other cancers.
Sensus Healthcare is looking to submit their new upcoming Intraoperative Radiation Therapy (IORT) device to FDA for approval by next month. Like I said before, this is the pinnacle IMO. Sensus Healthcare's IORT device will change the landscape of how breast cancer is treated (IMO). In a nutshell, a 3-5 minute procedure done with Sensus' 30" x 30" device on wheels, will replace 6 to 10 weeks of radiation therapy after a mastectomy or lumpectomy.
Market Opportunity... - Skin Cancer - 6M patients a year (10-14 treatments) - Keloids - 10M++ patients a year (3 treatments) - Psoriasis - 19M patients a year (10-14 treatments) - Breast and other cancers - ???
BTW, within the next few months Sensus will be making an acquisition (IMO) that will be accretive to sales and will/could add products that will contribute to a recurring revenue stream.
SRTS...2018 sleeper. Opened the year @ $5.22...Sensus Healthcare is an approx 5 yr old company that went public last year. Not profitable...yet. Could see an accretive acquisition along w/ an offering before Q1 is over. Already has FDA approval (SRT-100) for treating skin cancer and keloids in the US, China, and Mexico. Sensus also submitted a product to FDA approx a month ago which will allow for treatment of psoriasis. The kicker and thing to watch for in 2018, is the FDA submission and approval of Sensus Healthcare's Intraoperative Radiation Therapy (IORT) device. This will be a bonanza and will drive the stock price to new highs (IMO). Sensus is hoping to have the device submitted to FDA within the next month and approval sometime before year end...
Repost... "SRTS...Young company not profitable yet, but has high gross margins with no long term debt. They are rapidly increasing their sales, sales force and presence worldwide. Sensus Healthcare is a company w/ a proprietary non-invasive way to treat non-melanoma skin cancers, keloids, and possibly psoriasis, breast cancer, and more. Stay tuned."
From the 2017 Q3 cc... - "What I can tell you is that things are moving along as scheduled. So at current, we are building a system that is just about completed so that we can start its initial testing. And once we're comfortable with the product being able to pass any and all tests that are going to be required by the FDA, that's when we'll start the paperwork for the submission. So part of the reason why we've had such expense in R&D is, this was a product that was scheduled to come out maybe at the end of 2018. And if we can get it approved before the middle of next year, that just gives us significant runway to get some sales in-house because you have to keep in mind that this is a product that's going to be $800,000 to $900,000. So it's going to have significant revenue impact on the company, BUT IT'S GOING TO HAVE EVEN MORE SIGNIFICANT IMPACT IN THE TREATMENT OF PATIENTS. And that's what we're really excited about. THIS IS A GAME CHANGER AND A LIFESAVER FOR PEOPLE THAT HAVE BREAST CANCER. AND IT'S ALSO GOING TO APPLY TO CERTAIN HEAD AND NECK CANCERS, COLORECTAL, AND VAGINAL CANCERS. These things are what they call orphan cancers, and this is something that is going to be beneficial in those areas as well." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136141511&txt2find=srts
Sensus' IORT device has the potential to drastically change the landscape of how breast cancer is treated. In a nutshell, a 3-5 minute procedure done with Sensus Healthcare's 30" x 30" device on wheels, could/will replace 6 to 10 weeks of radiation therapy after a mastectomy or lumpectomy.
News 
Market Data 
Discover 
